Vascular Protection with Dipeptidyl Peptidase‐IV inhibitors in Diabetes: Experimental and Clinical Therapeutics

E-ISSN： 1875-9114|35|3|277-297

ISSN： 0277-0008

Source： PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol.35, Iss.3, 2015-03, pp. : 277-297

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 42, Iss. 10, 2015-10 ,pp. : 999-1024

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes

Current Drug Safety, Vol. 6, Iss. 5, 2011-11 ,pp. : 304-309

Bentham Science Publishers

Access to resources Recommend Favorite

Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 616-621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV

By Lambeir Anne-Marie Durinx Christine Scharpé Simon De Meester Ingrid

Critical Reviews in Clinical Laboratory Sciences, Vol. 40, Iss. 3, 2003-05 ,pp. : 209-294

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. S1, 2018-02 ,pp. : 68-76

John Wiley & Sons Inc

Access to resources Recommend Favorite